Jade Biosciences (JBIO) Net Equity Issued and Repurchased (2021 - 2024)
Jade Biosciences' (JBIO) quarterly Net Equity Issued and Repurchased came in at $307000.0 in Q4 2024, up 222.8% on a QoQ basis from -$250000.0 in Q4 2021.
Powered by 
Analysis
Jade Biosciences (JBIO) Net Equity Issued and Repurchased (2021 - 2024) Analysis & Trends
Jade Biosciences (JBIO) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $307000.0 in Q4 2024.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $307000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $307000.0 (down 99.52% YoY) and the FY2024 annual result came in at $23.9 million, down 46.66% from the prior year.
- Net Equity Issued and Repurchased advanced to $307000.0 in Q4 2024, from -$250000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $63.7 million in Q3 2021 to a low of -$250000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Jade Biosciences | 1.22 Bn | 1.22 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 307,000.00 |
| Dec 31, 2021 | -250,000.00 |
| Sep 30, 2021 | 63.68 Mn |
| Jun 30, 2021 | 55.53 Mn |
| Mar 31, 2021 | 7.98 Mn |